Quarry LP’s Aclaris Therapeutics ACRS Stock Holding History

Quarry LP’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,124	Closed	-$17.7K	–	1005
2022 Q4	$17.7K	Buy	+1,124	New	+$18.1K	﹤0.01%	413

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Quarry LP's ACRS Position: Q1 2023 in Review

Quarry LP sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 1,124 shares — an estimated $17.7K sold.

Quarry LP first reported a position in ACRS in Q4 2022 and held it in 1 quarter. The position peaked at $17.7K in Q4 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

Quarry LP reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
Quarry LP sold 1,124 Aclaris Therapeutics shares in Q1 2023, an estimated $17.7K.
Quarry LP first reported a position in Aclaris Therapeutics in Q4 2022 and held it in 1 quarter.
Quarry LP's Aclaris Therapeutics position peaked at $17.7K in Q4 2022.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on Quarry LP's 13F filing for Q1 2023, filed 15 May 2023.